In a study of an earlier randomized controlled trial of antipsychotics, researchers from Yale and the U.K found that second-generation antipsychotics were as likely as the first-generation antipsychotics to cause extrapyramidal symptoms. However, patients in the second-generation group were “dramatically” (30-fold) less likely to be prescribed medication for the management of these side effects. First-generation antipsychotics have the potential to “avoid life-shortening metabolic disturbances” caused by second-generation antipsychotics, but current psychiatrists have little or no experience with the prior generation of antipsychotics, the researchers said. Results will appear in the British Journal of Psychiatry.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Can you provide the reference for this?